JP2023029966A5 - - Google Patents

Download PDF

Info

Publication number
JP2023029966A5
JP2023029966A5 JP2022194564A JP2022194564A JP2023029966A5 JP 2023029966 A5 JP2023029966 A5 JP 2023029966A5 JP 2022194564 A JP2022194564 A JP 2022194564A JP 2022194564 A JP2022194564 A JP 2022194564A JP 2023029966 A5 JP2023029966 A5 JP 2023029966A5
Authority
JP
Japan
Prior art keywords
guide
seq
nucleotides
sequence
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022194564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023029966A (ja
JP7707140B2 (ja
Filing date
Publication date
Priority claimed from JP2020517500A external-priority patent/JP2021500864A/ja
Application filed filed Critical
Publication of JP2023029966A publication Critical patent/JP2023029966A/ja
Publication of JP2023029966A5 publication Critical patent/JP2023029966A5/ja
Priority to JP2025112164A priority Critical patent/JP2025163016A/ja
Application granted granted Critical
Publication of JP7707140B2 publication Critical patent/JP7707140B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022194564A 2017-09-29 2022-12-06 Ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスの治療用の組成物および方法 Active JP7707140B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025112164A JP2025163016A (ja) 2017-09-29 2025-07-02 Ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスの治療用の組成物および方法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762566236P 2017-09-29 2017-09-29
US62/566,236 2017-09-29
US201862671902P 2018-05-15 2018-05-15
US62/671,902 2018-05-15
JP2020517500A JP2021500864A (ja) 2017-09-29 2018-09-28 Ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスの治療用の組成物および方法
PCT/US2018/053382 WO2019067872A1 (en) 2017-09-29 2018-09-28 COMPOSITIONS AND METHODS FOR EDITING THE TTR GENE AND TREATING AMYLOID DOSE ATTR

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020517500A Division JP2021500864A (ja) 2017-09-29 2018-09-28 Ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスの治療用の組成物および方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025112164A Division JP2025163016A (ja) 2017-09-29 2025-07-02 Ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスの治療用の組成物および方法

Publications (3)

Publication Number Publication Date
JP2023029966A JP2023029966A (ja) 2023-03-07
JP2023029966A5 true JP2023029966A5 (https=) 2023-06-02
JP7707140B2 JP7707140B2 (ja) 2025-07-14

Family

ID=63858214

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020517500A Pending JP2021500864A (ja) 2017-09-29 2018-09-28 Ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスの治療用の組成物および方法
JP2022194564A Active JP7707140B2 (ja) 2017-09-29 2022-12-06 Ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスの治療用の組成物および方法
JP2025112164A Pending JP2025163016A (ja) 2017-09-29 2025-07-02 Ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスの治療用の組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020517500A Pending JP2021500864A (ja) 2017-09-29 2018-09-28 Ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスの治療用の組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025112164A Pending JP2025163016A (ja) 2017-09-29 2025-07-02 Ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスの治療用の組成物および方法

Country Status (16)

Country Link
US (4) US20200248180A1 (https=)
EP (1) EP3688161A1 (https=)
JP (3) JP2021500864A (https=)
KR (1) KR20200058509A (https=)
CN (2) CN118530993A (https=)
AU (2) AU2018338787C1 (https=)
BR (1) BR112020005287A2 (https=)
CA (1) CA3077251A1 (https=)
CO (1) CO2020005116A2 (https=)
IL (3) IL311170B1 (https=)
MX (2) MX2020003608A (https=)
MY (1) MY203849A (https=)
PH (1) PH12020550364A1 (https=)
SG (1) SG11202002565YA (https=)
TW (1) TWI904069B (https=)
WO (1) WO2019067872A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
MX394999B (es) 2017-09-29 2025-03-24 Regeneron Pharma Animales no humanos que comprenden un locus ttr humanizado y metodos de uso
JP7543259B2 (ja) 2018-10-18 2024-09-02 アクイタス セラピューティクス インコーポレイテッド 活性剤の脂質ナノ粒子送達のための脂質
AU2020248337A1 (en) * 2019-03-28 2021-11-04 Intellia Therapeutics, Inc. Compositions and methods for ttr gene editing and treating ATTR amyloidosis comprising a corticosteroid or use thereof
EP3946598A1 (en) * 2019-03-28 2022-02-09 Intellia Therapeutics, Inc. Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent
BR112021019224A2 (pt) * 2019-03-28 2021-11-30 Intellia Therapeutics Inc Polinucleotídeos, composições e métodos para expressão de polipeptídeo
US11891618B2 (en) 2019-06-04 2024-02-06 Regeneron Pharmaceuticals, Inc. Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
MX2022006950A (es) * 2019-12-11 2022-11-07 Intellia Therapeutics Inc Arn guía modificados para edición de genes.
EP4237005A4 (en) * 2020-10-28 2024-10-09 Novo Nordisk A/S ANTI-TRANSTHYRETIN ANTIBODIES AND METHODS OF USE THEREOF
CR20230305A (es) 2020-12-11 2023-11-10 Intellia Therapeutics Inc Polinucleótidos, composiciones y métodos para la edición del genoma que implican desaminación
CN112795595A (zh) * 2020-12-24 2021-05-14 中山大学 一种遗传性转甲状腺素蛋白淀粉样变性疾病的基因治疗系统
WO2022246266A1 (en) * 2021-05-21 2022-11-24 Beam Therapeutics Inc. Base editing of transthyretin gene
KR20240038705A (ko) 2021-06-22 2024-03-25 인텔리아 테라퓨틱스, 인크. 간 유전자의 생체 내 편집 방법
US20250127927A1 (en) * 2021-08-23 2025-04-24 The Board Of Trustees Of The Leland Stanford Junior University Targeted integration at beta-globin locus in human hematopoietic stem and progenitor cells
AU2022345881A1 (en) 2021-09-20 2024-03-21 Alnylam Pharmaceuticals, Inc. Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
CN116064598B (zh) * 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
WO2023185697A2 (en) * 2022-03-29 2023-10-05 Accuredit Therapeutics (Suzhou) Co., Ltd. Compositions and methods for treatment of transthyretin amyloidosis
WO2024003805A1 (en) * 2022-06-30 2024-01-04 Geneditbio Limited Methods and compositions for ttr gene editing and therapy using crispr system
TW202417017A (zh) * 2022-06-30 2024-05-01 香港商正基基因科技有限公司 具有化學修飾的導引rna
CN118853659A (zh) * 2023-04-14 2024-10-29 深圳瑞吉生物科技有限公司 提高mRNA翻译蛋白的输出量的核酸及其应用
WO2024259135A1 (en) 2023-06-13 2024-12-19 Intellia Therapeutics, Inc. Assays for analysis of ribonucleic acid (rna) molecules
CN120265763A (zh) * 2023-10-25 2025-07-04 上海津曼特生物科技有限公司 靶向ttr的基因编辑组合物
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
KR940703846A (ko) 1991-12-24 1994-12-12 비. 린네 파샬 갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides)
US6169169B1 (en) 1994-05-19 2001-01-02 Dako A/S PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
WO2006007712A1 (en) 2004-07-19 2006-01-26 Protiva Biotherapeutics, Inc. Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
WO2010017509A1 (en) 2008-08-07 2010-02-11 Isis Pharmaceuticals, Inc. Modulation of transthyretin expression for the treatment of cns related disorders
EA036772B1 (ru) 2008-10-20 2020-12-18 Элнилэм Фармасьютикалз, Инк. Композиции и способы для ингибирования экспрессии транстиретина
US9101643B2 (en) 2009-11-03 2015-08-11 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
RS56011B1 (sr) 2010-04-29 2017-09-29 Ionis Pharmaceuticals Inc Modulacija ekspresije transtiretina
HUE048622T2 (hu) 2011-11-18 2020-08-28 Alnylam Pharmaceuticals Inc RNSi szerek, készítmények és alkalmazási eljárások transztiretin (TTR) asszociált betegségek kezelésére
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
DK2931897T3 (en) * 2012-12-12 2018-02-05 Broad Inst Inc CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS
DK2931898T3 (en) 2012-12-12 2016-06-20 Massachusetts Inst Technology CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
CA2895155C (en) 2012-12-17 2021-07-06 President And Fellows Of Harvard College Rna-guided human genome engineering
EP3608308B1 (en) 2013-03-08 2021-07-21 Novartis AG Lipids and lipid compositions for the delivery of active agents
SI2986729T1 (sl) 2013-04-16 2019-02-28 Regeneron Pharmaceuticals, Inc. Ciljana sprememba genoma podgane
DK2991656T3 (da) 2013-05-01 2020-03-23 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
KR20160019553A (ko) * 2013-06-17 2016-02-19 더 브로드 인스티튜트, 인코퍼레이티드 유사분열 후 세포의 질병 및 장애를 표적화하고 모델링하기 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
ES2895651T3 (es) 2013-12-19 2022-02-22 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
CN106687601A (zh) * 2014-05-28 2017-05-17 株式会社图尔金 使用靶特异性核酸酶灵敏检测靶dna的方法
KR102386101B1 (ko) * 2014-06-26 2022-04-14 리제너론 파마슈티칼스 인코포레이티드 표적화된 유전자 변형을 위한 방법 및 그 조성물, 및 사용 방법
EP3169309B1 (en) 2014-07-16 2023-05-10 Novartis AG Method of encapsulating a nucleic acid in a lipid nanoparticle host
EP3265559B1 (en) 2015-03-03 2021-01-06 The General Hospital Corporation Engineered crispr-cas9 nucleases with altered pam specificity
WO2017053431A2 (en) * 2015-09-21 2017-03-30 Arcturus Therapeutics, Inc. Allele selective gene editing and uses thereof
ES2964690T3 (es) 2015-09-21 2024-04-09 Trilink Biotechnologies Llc Método para sintetizar ARN con caperuza 5'
CA2999649A1 (en) * 2015-11-06 2017-05-11 Crispr Therapeutics Ag Materials and methods for treatment of glycogen storage disease type 1a
CA3006618A1 (en) * 2015-12-01 2017-06-08 Crispr Therapeutics Ag Materials and methods for treatment of alpha-1 antitrypsin deficiency
US11083799B2 (en) * 2016-03-16 2021-08-10 Crispr Therapeutics Ag Materials and methods for treatment of hereditary haemochromatosis
TWI773666B (zh) * 2016-03-30 2022-08-11 美商英特利亞醫療公司 Crispr/cas 組分之脂質奈米粒子調配物
WO2018007871A1 (en) * 2016-07-08 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of transthyretin amyloidosis
AU2017374044B2 (en) 2016-12-08 2023-11-30 Intellia Therapeutics, Inc. Modified guide RNAs

Similar Documents

Publication Publication Date Title
JP2023029966A5 (https=)
JP2021500864A5 (https=)
IL311170A (en) Compositions and methods for ttr gene editing and treating attr amyloidosis
US20250025580A1 (en) Compositions and Methods for Treatment of Diseases Associated with Trinucleotide Repeats in Transcription Factor Four
JP2020501582A5 (https=)
AU749410B2 (en) In vivo use of recombinagenic oligonucleobases to correct genetic lesions in hepatocytes
US6096720A (en) Liposomal oligonucleotide compositions
JP2002534353A (ja) 高脂血症の遺伝子治療のための方法および化合物
CN101448945A (zh) 用于诱导外显子跳跃的手段和方法
RS54944B1 (sr) Oligonukleotidi za pravljenje promena u sekvencama ciljanih rnk molekula prisutnih u živoj ćeliji
JP2017510583A (ja) 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的ｕｎａオリゴマー
WO2025166988A1 (zh) 一种肾脏靶向mRNA-LNP递送技术和疾病治疗方法
KR20200011899A (ko) 인위적인 유전자 조작을 통한 자가면역질환 치료
JPWO2020198697A5 (https=)
US20240191228A1 (en) Antisense oligonucleotides for treatment of neurological disorders
JP2001511171A (ja) 安定化したカチオン性トランスフェクション用物質／核酸粒子の配合物
CN111133110A (zh) 用于重复扩增突变的基因组编辑系统
WO2024036186A2 (en) Identification of allele-specific target sequences for c9orf72
JPWO2004026343A1 (ja) 部位特異的遺伝子変換促進剤および遺伝子疾患治療剤
NZ762942B2 (en) Compositions and methods for ttr gene editing and treating attr amyloidosis
WO2026008077A1 (en) Modified grna for gene editing using crispr/cas system
WO2025128134A1 (en) Crispri targeting alpha-synuclein
US20020137717A1 (en) Use of chimeric mutational vectors to change endogenous nucleotide sequences in solid tissues
WO2022035984A1 (en) Antisense oligonucleotides for treatment of conditions and diseases related to trem2
EP4638751A2 (en) Compositions and methods for treating hnrnph2-related disorders